Modality
Cell Therapy
MOA
BCMA ADC
Target
MET
Pathway
Tau
SCD
Development Pipeline
Preclinical
~Oct 2014
→ ~Jan 2016
Phase 1
~Apr 2016
→ ~Jul 2017
Phase 2
~Oct 2017
→ ~Jan 2019
Phase 3
~Apr 2019
→ ~Jul 2020
NDA/BLA
~Oct 2020
→ ~Jan 2022
Approved
Apr 2022
→ Apr 2029
ApprovedCurrent
NCT03482378
2,828 pts·SCD
2022-04→2029-04·Completed
NCT03485685
1,129 pts·SCD
2025-09→TBD·Not yet recruiting
3,957 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2029-04-123.0y awayPh3 Readout· SCD
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
Approved
Complet…
Approved
Not yet…
Catalysts
Ph3 Readout
2029-04-12 · 3.0y away
SCD
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03482378 | Approved | SCD | Completed | 2828 | CfB |
| NCT03485685 | Approved | SCD | Not yet recr... | 1129 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| RVM-274 | Revolution Medicines | Phase 3 | MET | |
| Tixatapinarof | Recursion | Approved | FGFR | |
| Terazumab | Recursion | Phase 3 | AHR | |
| Talazasiran | Kymera | NDA/BLA | MET |